# GLP-1

Type: Technology

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/glp-1
Canonical HTML page: https://gethealthbrief.com/entity/glp-1

## Timeline

- **2026-01-01**: Payer Agreement Shift — New payer contracts take effect, shifting GTN expectations to the high 30% range for the fiscal year.
- **2025-12-31**: Q4 Milestone — Patient count surpasses 36,000 and quarterly revenue exceeds $320 million.
- **2025-09-30**: GLP-1 Strategic Acquisition — Madrigal makes a $120 million upfront payment for an oral GLP-1 asset to expand its metabolic pipeline.
- **2025-01-01**: Rezdiffra Full-Year Launch — Madrigal begins its first full year of commercial sales for the first-ever approved MASH treatment.

## Recent coverage (4 stories)

### FDA Issues Warning to Novo Nordisk Over GLP-1 Adverse Event Reporting
2026-03-12 23:24:58 · Sentiment: Negative · Impact: 7/10 · Sources: 3

The FDA has issued a formal warning letter to Novo Nordisk for failing to properly report serious adverse events, including deaths and strokes, related to its GLP-1 medications. This regulatory escalation coincides with a significant market valuation decline and intensifying competition from compounding pharmacies.
Full story: https://gethealthbrief.com/story/fda-warning-novo-nordisk-glp1-reporting-failures

### Hims & Hers to Halt Compounded GLP-1 Sales Following Legal Settlement
2026-03-09 17:34:05 · Sentiment: Negative · Impact: 6/10 · Sources: 2

Hims & Hers Health has agreed to cease the sale of compounded GLP-1 medications as part of a legal settlement, marking a significant shift in its weight-loss business strategy. This move follows mounting pressure from pharmaceutical manufacturers and highlights the tightening regulatory environment for telehealth platforms leveraging drug shortages.
Full story: https://gethealthbrief.com/story/hims-hers-settles-glp1-lawsuit-compounding

### Agilent Navigates Tariff Headwinds and Academic Softness in Q1 2026
2026-02-26 00:37:03 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Agilent Technologies reported a resilient Q1 2026 with $1.8 billion in revenue, driven by a 7% growth in the pharma sector despite significant headwinds in academic and government funding. While the company faced a 100-basis-point gross margin compression due to rising tariffs and weather disruptions, strong performance in the Agilent CrossLab Group suggests a shift toward service-oriented recurring revenue.
Full story: https://gethealthbrief.com/story/agilent-q1-2026-earnings-analysis-healthcare-it

### Madrigal Pharmaceuticals Triples Q4 Revenue as Rezdiffra Adoption Accelerates
2026-02-24 00:09:59 · Sentiment: Positive · Impact: 7/10 · Sources: 5

Madrigal Pharmaceuticals reported a transformative Q4 2025, with Rezdiffra net sales reaching $321.1 million and a patient base exceeding 36,000. The company is aggressively expanding its metabolic pipeline, integrating GLP-1 and siRNA technologies to solidify its leadership in the MASH market.
Full story: https://gethealthbrief.com/story/madrigal-q4-2025-earnings-rezdiffra-mash-market

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.